Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|November 20, 2026

Merck TROP2 ADC Meets Survival End Point in Gastroesophageal Cancer

Listen
0:00 / 0:00

Key Takeaways

  • TroFuse-015 randomized 473 patients to sac-TMT 4 mg/kg on days 1, 15, and 29 every 6 weeks or physician’s-choice trifluridine-tipiracil, irinotecan, paclitaxel, or docetaxel.
  • Overall survival superiority was achieved without a corresponding blinded central review progression-free survival benefit, raising questions about effect kinetics, post-progression therapy, and endpoint discordance.
SHOW MORE

Sacituzumab tirumotecan is the first TROP2-directed ADC to improve overall survival in heavily pretreated gastroesophageal adenocarcinoma.

Merck announced on November 20, 2026, that its phase 3 TroFuse-015 trial of sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC), met its primary end point of overall survival (OS) in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received 2 or more prior lines of systemic therapy.¹ Merck said in a company press release that the trial is the first time a TROP2-directed ADC has shown an OS benefit in a global phase 3 trial in this population.¹

Key facts

  • Drug: sacituzumab tirumotecan (sac-TMT; Merck, licensed from Kelun-Biotech)
  • Class: TROP2-directed antibody-drug conjugate (belotecan-derived topoisomerase I inhibitor payload)
  • Indication studied: Locally advanced unresectable or metastatic gastroesophageal adenocarcinoma, third line or later
  • Trial: TroFuse-015 (NCT06356311); phase 3, randomized, open-label, n=473
  • Comparator: Treatment of physician's choice (trifluridine-tipiracil, irinotecan, paclitaxel, or docetaxel)
  • Dosing: 4 mg/kg on days 1, 15, and 29 of each 6-week cycle
  • Primary end point met: Overall survival; numeric results not disclosed
  • Secondary end points: Progression-free survival not met; response rate nominally favored sac-TMT
  • Safety: No new safety signals
  • Program: 18 ongoing global phase 3 trials; second positive phase 3 readout

“There is a tremendous unmet need for therapies that can improve survival for these patients,” said Marjorie Green, MD, senior vice president and head of oncology, global clinical development, at Merck Research Laboratories, in the release.¹

Did sacituzumab tirumotecan improve overall survival in gastroesophageal cancer?

At final analysis, sac-TMT produced a statistically significant and clinically meaningful improvement in OS compared with treatment of physician's choice (TPC), and results were generally consistent across subgroups regardless of TROP2 expression status.¹ Sac-TMT did not meet the secondary end point of progression-free survival assessed by blinded independent central review.¹ Objective response rate, another secondary end point, nominally favored sac-TMT, but that comparison was not formally tested under the prespecified analysis plan.¹ The safety profile was consistent with previously reported sac-TMT studies, with no new safety signals.¹ Merck did not disclose numeric results, which it said will be presented at an upcoming medical meeting and shared with regulatory authorities.¹

How is the TroFuse-015 trial structured and who participated?

TroFuse-015 (NCT06356311) is a randomized, open-label, multicenter global trial that enrolled 473 patients.¹ Participants received either sac-TMT at 4 mg/kg on days 1, 15, and 29 of each 6-week cycle, or TPC consisting of trifluridine-tipiracil, irinotecan, paclitaxel, or docetaxel.¹ Secondary end points include progression-free survival, objective response rate, and duration of response.¹

How does sac-TMT work?

Sac-TMT is a TROP2-directed ADC with a belotecan-derived topoisomerase I inhibitor payload and a bifunctional linker designed to maximize payload delivery to tumor cells and limit payload loss in circulation.¹ TROP2 is overexpressed on tumor cells compared with healthy cells in many common cancers.¹ Kelun-Biotech developed the molecule and granted Merck exclusive rights to develop, manufacture, and commercialize it outside Greater China.¹

What other cancers is sacituzumab tirumotecan being tested for?

TroFuse-015 is the second positive phase 3 readout from the TroFuse program, which comprises 18 ongoing global phase 3 trials spanning more than 9 disease areas and more than 15,000 patients.¹ Merck said 14 of the 18 studies pursue first-in-class opportunities.¹ In the TroFuse-005 trial in 776 patients with previously treated endometrial cancer, sac-TMT extended median OS to 19.0 months vs 12.1 months with chemotherapy (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.55-0.84; P<.0001) and median progression-free survival to 7.2 months vs 3.9 months.² Those data were published in The Lancet, and FDA accepted a biologics license application with a target action date of June 15, 2027.²

Sac-TMT also has peer-reviewed phase 3 data in lung cancer. In epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer that progressed after EGFR tyrosine kinase inhibitor therapy, sac-TMT monotherapy extended median progression-free survival to 8.3 months vs 4.3 months with pemetrexed plus platinum chemotherapy (HR, 0.49; 95% CI, 0.39-0.62) among 376 patients.³

Why does this matter in gastroesophageal cancer?

Gastroesophageal adenocarcinoma comprises gastric, gastroesophageal junction, and esophageal adenocarcinomas (EAC).¹ Adenocarcinomas account for approximately 90% to 95% of gastric malignancies, and gastric cancer often causes no symptoms early, making detection before advanced disease difficult.¹ Merck estimates approximately 31,500 new US cases of gastric cancer and 10,700 deaths in 2026 and more than 14,300 new EAC cases.¹ Targeted options have advanced in earlier lines. For example, FDA approved zanidatamab-hrii (Ziihera), a bispecific HER2-directed antibody, for first-line HER2-positive gastroesophageal adenocarcinoma in August 2026.⁴

What are the limitations?

Merck disclosed no hazard ratios, median survival values, or p-values for TroFuse-015, so the magnitude of the OS benefit is unknown. The trial missed its progression-free survival end point, and the response rate comparison was not formally tested. The results are topline, have not been peer reviewed, and no regulatory submission has been announced. The trial was open-label, which can influence assessment of some outcomes, and the epidemiology figures are Merck's estimates.

References

  1. Merck. Merck announces TroFuse-015 trial evaluating sacituzumab tirumotecan (sac-TMT) met primary endpoint of overall survival (OS) in third-line or later locally advanced unresectable or metastatic gastroesophageal adenocarcinoma. Press release. Published November 20, 2026. Accessed November 20, 2026. https://www.merck.com/news/merck-announces-trofuse-015-trial-evaluating-sacituzumab-tirumotecan-sac-tmt-met-primary-endpoint-of-overall-survival-os-in-third-line-or-later-locally-advanced-unresectable-or-metastatic-gastroes/
  2. Merck. Sacituzumab tirumotecan (sac-TMT) reduced the risk of death by 32% and the risk of disease progression or death by 41% compared to chemotherapy in certain patients with advanced or recurrent endometrial cancer. Press release. Published October 26, 2026. Accessed November 20, 2026. https://www.merck.com/news/sacituzumab-tirumotecan-sac-tmt-reduced-the-risk-of-death-by-32-and-the-risk-of-disease-progression-or-death-by-41-compared-to-chemotherapy-in-certain-patients-with-advanced-or-recurrent-endometrial/
  3. Fang W, Wu L, Meng X, et al. Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC. N Engl J Med. 2026;394(1):13-26. doi: 10.1056/NEJMoa2512071
  4. Zymeworks. US FDA approves Ziihera (zanidatamab-hrii) with and without tislelizumab plus chemotherapy in first-line HER2+ advanced gastroesophageal adenocarcinoma. Press release. Published August 25, 2026. Accessed November 20, 2026. https://ir.zymeworks.com/news-releases/news-release-details/us-fda-approves-ziiherar-zanidatamab-hrii-and-without

Related to this article